Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 10,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, February 18th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00.
• On Monday, February 10th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00.
• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $353.64, for a total value of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $370.71, for a total value of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total value of $3,619,500.00.

United Therapeutics Trading Down 0.2 %

Shares of NASDAQ UTHR opened at $357.50 on Wednesday. The firm has a market capitalization of $15.96 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 0.97 and a beta of 0.57. The business has a 50-day moving average of $361.95 and a 200-day moving average of $361.11. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Milestone Asset Management LLC boosted its stake in United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 1,037 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after buying an additional 789 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in United Therapeutics by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after buying an additional 50,291 shares in the last quarter. Franklin Resources Inc. boosted its stake in United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares in the last quarter. Finally, Burney Co. boosted its stake in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after buying an additional 12,705 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.